CD8A and neoplasm: Some groups have engineered VSV to express human papillomavirus oncogene E7 [79] or human oncofetal antigen 5T4 [80], which generate CD4+ and CD8+ T cell-specific responses that traffic to the tumor site when administered intratumorally in mice with melanoma and colorectal cancer xenografts.